Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates

Launched by SHANDONG UNIVERSITY · May 22, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of cefuroxime, an antibiotic, in newborns who are 28 days old or younger. Cefuroxime is used to treat bacterial infections, but we don't have enough information about how it works in very young patients. The goal of this study is to understand how the drug is processed in the body, how effective it is at treating infections, and whether it is safe for these infants.

To participate, babies need to be 28 days old or younger and must be receiving cefuroxime as part of their treatment. Parents will need to give written consent for their baby to join the study. Unfortunately, babies who are not expected to survive the treatment period or who are receiving other trial medications will not be eligible. If a baby does join the trial, parents can expect close monitoring to ensure the safety and effectiveness of cefuroxime during the treatment. Overall, this study aims to gather important information that could help improve the care of newborns with infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: postnatal age ≤28 days;
• • Cefuroxime used as part of antimicrobial treatment;
• • Parental written consent.
• Exclusion Criteria:
• • Expected survival time less than the treatment cycle;
• • Receiving other systemic trial drug therapy;
• • Other factors that the researcher considers unsuitable for inclusion.